![RuCl(p-cymene)[(R,R)-Ts-DPEN] (RuCl[(R,R)-Tsdpen](p-cymene))](/upload/1124/V65170.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
RuCl(p-cymene)[(R,R)-Ts-DPEN] does not have a biological target as it is a transition metal catalyst rather than a pharmacologically active compound. Its function is chemical—it catalyzes asymmetric transfer hydrogenation reactions, enabling the enantioselective reduction of prochiral ketones and imines to chiral alcohols and amines. The ruthenium center facilitates hydride transfer from a hydrogen donor (typically formate or 2-propanol) to the substrate, while the chiral Ts-DPEN ligand induces enantioselectivity. The compound itself is not designed for therapeutic use and has no specific biological targets. Its interactions are limited to chemical substrates in catalytic reactions, and it is not evaluated for biological activity.
|
|---|---|
| ln Vitro |
In vitro, RuCl(p-cymene)[(R,R)-Ts-DPEN] exhibits no pharmacological activity as it is a chemical catalyst. Its utility is demonstrated in asymmetric transfer hydrogenation reactions, where it catalyzes the enantioselective reduction of ketones and imines with high enantioselectivity (typically >90% ee). The catalyst is widely used in the synthesis of chiral pharmaceuticals, agrochemicals, and fine chemicals. In cell-based assays, the compound is not tested for biological activity. Its role is strictly chemical—providing enantioselective reduction capabilities for the synthesis of chiral drug intermediates. The compound is used exclusively in organic synthesis and catalysis research, not in biological or pharmacological screening.
|
| ln Vivo |
RuCl(p-cymene)[(R,R)-Ts-DPEN] is not a pharmacologically active agent and does not exhibit in vivo therapeutic activity. It is used as a chemical catalyst in organic synthesis for the preparation of enantiomerically enriched compounds. The compound is not intended for human or animal exposure. It is used exclusively in laboratory and industrial settings for chemical synthesis. No therapeutic efficacy has been reported for this compound. The compound is not administered to animals in pharmacological studies and has no known physiological effects. Its role is strictly catalytic—facilitating enantioselective reduction reactions in organic synthesis for drug discovery and development.
|
| Enzyme Assay |
In vitro assays for RuCl(p-cymene)[(R,R)-Ts-DPEN] focus on its catalytic activity rather than receptor binding. A standard protocol for asymmetric transfer hydrogenation involves dissolving the catalyst (0.1-1 mol%) in a suitable solvent (e.g., 2-propanol or formic acid/triethylamine mixture) with the substrate (ketone or imine). The reaction is typically carried out at room temperature to 80°C for 2-24 hours. Conversion and enantiomeric excess are monitored by GC or HPLC using chiral columns. For quality control, the catalyst is characterized by NMR (¹H, ¹³C), elemental analysis, and HPLC purity (>97%). The compound should be stored under inert atmosphere at room temperature.
|
| Cell Assay |
Cell-based experiments are not performed with RuCl(p-cymene)[(R,R)-Ts-DPEN], as it is a chemical catalyst rather than a test compound for biological activity. The compound is used exclusively in chemical synthesis and catalysis applications. No cytotoxicity or cell viability studies are conducted with this compound as it is not intended for biological applications. The compound is handled with standard laboratory precautions for metal catalysts, including the use of gloves, safety glasses, and working in a fume hood. The compound is not evaluated in cellular systems due to its lack of biological activity and potential toxicity as a heavy metal complex.
|
| Animal Protocol |
In vivo animal studies are not conducted with RuCl(p-cymene)[(R,R)-Ts-DPEN], as it is a chemical catalyst rather than a therapeutic test article. The compound is not used in pharmacological or toxicological studies in animals. Its applications are limited to chemical synthesis and catalysis research. No in vivo efficacy or safety studies have been reported for this compound. The compound is not administered to animals as it is not intended for biological or therapeutic applications. Any ruthenium residues in drug substances synthesized using this catalyst are removed during purification processes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of RuCl(p-cymene)[(R,R)-Ts-DPEN] are not characterized as it is not a drug substance. Based on its physicochemical properties (molecular weight 636.21, high lipophilicity, metal-containing), the compound would be expected to have very low oral bioavailability due to poor water solubility and high molecular weight. If absorbed, ruthenium complexes can be toxic and may interact with proteins and DNA. However, the compound is not intended for human exposure and has not been evaluated in formal pharmacokinetic studies. In pharmaceutical synthesis, residual ruthenium is removed during workup to meet regulatory limits for heavy metals in drug substances.
|
| Toxicity/Toxicokinetics |
RuCl(p-cymene)[(R,R)-Ts-DPEN] may be harmful if swallowed, inhaled, or in contact with skin. The compound contains ruthenium, which can be toxic. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood. The compound should be stored at room temperature under inert atmosphere. No acute toxicity data are available. The compound is not intended for drug, household, or other uses. Special care should be taken to avoid inhalation of dust and contact with skin and eyes. In case of exposure, rinse with water and seek medical attention.
|
| Additional Infomation |
RuCl(p-cymene)[(R,R)-Ts-DPEN] is a widely used Noyori-type asymmetric transfer hydrogenation catalyst developed by the Noyori group. It is also known as (R,R)-Ts-DPEN-RuCl(p-cymene). The catalyst enables the enantioselective reduction of ketones and imines to chiral alcohols and amines with high enantioselectivity, making it invaluable in the synthesis of chiral pharmaceuticals, agrochemicals, and fine chemicals. The compound has not undergone clinical trials and is not approved as a pharmaceutical. Its mechanism of action is catalytic—facilitating hydride transfer from a hydrogen donor to substrates through a metal-ligand cooperative mechanism.
|
| Molecular Formula |
C31H35CLN2O2RUS
|
|---|---|
| Molecular Weight |
636.21
|
| Exact Mass |
630.068
|
| CAS # |
192139-92-7
|
| Appearance |
Yellow to brown solid powder
|
| Melting Point |
215 °C
|
| LogP |
8.521
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5718 mL | 7.8590 mL | 15.7181 mL | |
| 5 mM | 0.3144 mL | 1.5718 mL | 3.1436 mL | |
| 10 mM | 0.1572 mL | 0.7859 mL | 1.5718 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
